DDInter1533 DDInter1658
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Promethazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propiomazine
Promethazine {u} (Compound) resembles {v} (Compound) Chlorprothixene
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promethazine {u} (Compound) binds {v} (Gene) CALM3
Promethazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Promethazine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Promethazine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Promethazine (Compound) resembles Ethopropazine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Promethazine (Compound) resembles Chlorprothixene (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promethazine (Compound) binds CALM3 (Gene)
Promethazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Promethazine (Compound) causes Decreased appetite (Side Effect)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Promethazine may lead to a major life threatening interaction when taken with Toremifene